Jonathan Ejie | Personalized Medicine | Best Research Article Award

Published on by Top Pharmaceutical

Jonathan Ejie | Personalized Medicine | Best Research Article Award

Mr. Jonathan Ejie, UCSF, United States

Mr. Jonathan Ejie is an aspiring physician-scientist currently pursuing his M.D. at UCSF 🩺 (Class of 2026), following a B.S. in Electrical Engineering & Computer Science from UC Berkeley 💻. His research spans oncology, radiology, and AI in healthcare, with published work in Cancers (2025) and upcoming studies in Nature Communications 📊. Jonathan integrates data science 🧠 with clinical insights, contributing to health equity, quality improvement, and surgical education. A mentor, tutor, and award-winning leader 🏅, he co-founded the UCSF Futbol Club and serves underserved communities through advocacy and outreach.

Publication Profile 

Orcid

Education

Mr. Jonathan Ejie is an exceptional scholar whose educational journey bridges medicine and technology. He is currently pursuing his Doctor of Medicine (M.D.) degree at the prestigious University of California, San Francisco (UCSF) 🏥, with an expected graduation in 2026. Prior to this, he earned a Bachelor of Science in Electrical Engineering and Computer Science (EECS) 💻 from the University of California, Berkeley, graduating in 2022. His strong foundation in both engineering and clinical science equips him with a unique interdisciplinary perspective 🤖🩺, positioning him at the forefront of innovation in digital health and precision medicine.

Experience

Mr. Jonathan Ejie brings a blend of academic support and compassionate service to his professional journey. As an MCAT Physics Tutor at UCSF (2023), he guided 15+ students through complex physics concepts 📘⚛️. Earlier, at Contra Costa College (2019–2021), he tutored mathematics from Algebra to Calculus ➕📐. His volunteer work includes providing first aid at athletic events 🏃‍♂️🩹, teaching surgical skills to high school students at UCSF 🧵🧑‍⚕️, and serving as a Health Advocate at West County Health Center 💬🩺, helping underserved patients access vital community resources. His dedication reflects a strong commitment to both education and public health.

Awards

Mr. Jonathan Ejie has been recognized for his academic excellence and impactful contributions to medicine and research. In 2024, he was honored with the prestigious Sinkler Miller Medical Association Scholarship 🎖️, sponsored by Gilead, celebrating his commitment to health equity and academic distinction. He also received the UCSF School of Medicine Summer Explore Fellowship Grant 🌟, supporting his innovative pursuits in medical research. In May 2023, Jonathan earned the Inquiry Conference Travel and Dissemination Award ✈️📊, which enabled him to share his scholarly findings on a larger stage. These accolades reflect his rising potential and leadership in healthcare.

Research Focus 

Mr. Jonathan Ejie’s research focus lies at the intersection of oncology, health disparities, and medical data science. His standout work on the “Ongoing Failure to Deliver Guideline-Concordant Care for Patients with Pancreatic Cancer” 📉🩺 highlights critical inequities in healthcare delivery across race, geography, and insurance status. Combining his background in medicine 🧑‍⚕️ and computer science 💻, Jonathan leverages data analysis and machine learning 🤖📊 to drive systemic improvements in cancer care. His work reflects a commitment to equity, evidence-based medicine, and the pursuit of personalized, accessible treatment strategies for vulnerable cancer populations.

Publication Top Notes

  • Ongoing Failure to Deliver Guideline-Concordant Care for Patients with Pancreatic Cancer

Jian Shi | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Jian Shi | Precision Medicine | Best Researcher Award

Assoc. Prof. Dr. Jian Shi, Neurology of UCSF, United States

Assoc. Prof. Dr. Jian Shi is a distinguished neuroscientist at the University of California, San Francisco, with a Ph.D. in Neurobiology from Navy Medical University, China. 🧬 He completed postdoctoral training at the University of Texas Southwestern Medical Center, focusing on neuroscience. His research integrates brain injury, neurodegenerative diseases, and glioblastoma with cutting-edge AI and bioinformatics tools. 🧪🧠 Dr. Shi has authored highly cited publications and received numerous accolades, including the APS Outstanding Paper Award. 🌟 A dedicated mentor and educator, he actively contributes to diversity and public service in neurology and biomedical research.

Publication Profile

Google Scholar

Education

Assoc. Prof. Dr. Jian Shi began his academic journey at the National University of Defense Technology in Hunan Province, China, earning both his B.S. and M.S. degrees in Biomechanics. ⚙️📘 He then pursued his Ph.D. in Neurobiology under the mentorship of Dr. Lu Changlin at the prestigious Navy Medical University in Shanghai. 🧬🏥 Driven by a passion for neuroscience, he completed his postdoctoral training at the University of Texas Southwestern Medical Center under the guidance of Dr. Steven G. Kernie, focusing on advanced neuroscience research. 🧠🔬 His academic foundation bridges biomechanics and cutting-edge neurobiological science.

Awards

Assoc. Prof. Dr. Jian Shi has received numerous accolades recognizing his excellence in research and education. 🇨🇳 He was honored with the prestigious National Award for Scientific Progress, Level 2 in China 🥇🔬 and received the Award for Outstanding Scientists from Navy Medical University, where he also earned the Best Teacher Award for his commitment to academic excellence 👨‍🏫🌟. His groundbreaking work earned him the “Top 50 Most Cited Article Award” from the Journal of Clinical Medicine 📖📈 and the APS Outstanding Paper Award from Acta Pharmacologica Sinica 🧪🏅. He is also recognized as a Trusted Reviewer by the International Journal of Molecular Sciences 🧠✅.

Research Focus

Assoc. Prof. Dr. Jian Shi’s research centers around neurobiology, with a strong emphasis on traumatic brain injury (TBI) 🧠💥, neurodegeneration 🧬, neurogenesis 🌱, and molecular neuroscience. His work explores small molecule therapies, microglial activation, intranasal drug delivery 💊, and microRNA biomarkers, particularly in the context of glioblastoma and stroke. He also investigates brain repair mechanisms, exosomal signaling 📦, and neurotrophin-mimetic compounds. In recent years, his interdisciplinary work has extended to climate impact models 🌍 and machine learning applications 🤖 in brain science, reflecting a comprehensive and innovative research portfolio in translational neuroscience and brain health.

Publication Top Notes

Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents

Microglial activation induced by brain trauma is suppressed by post-injury treatment with a PARP inhibitor

Intranasal administration with NAD+ profoundly decreases brain injury in a rat model of transient focal ischemia

Considering exosomal miR-21 as a biomarker for cancer

The basic helix-loop-helix transcription factor olig2 is critical for reactive astrocyte proliferation after cortical injury

A small molecule p75NTR ligand protects neurogenesis after traumatic brain injury

MicroRNAs as biomarkers for human glioblastoma: progress and potential

Regulatory networks between neurotrophins and miRNAs in brain diseases and cancers

Triggering receptor expressed on myeloid cells-2 expression in the brain is required for maximal phagocytic activity and improved neurological outcomes following experimental …

Beneficial effects of minocycline and botulinum toxin–induced constraint physical therapy following experimental traumatic brain injury

Mario Leporace | Personalized Medicine | Best Innovation Award

Published on by Top Pharmaceutical

Mario Leporace | Personalized Medicine | Best Innovation Award

Prof. Dr. Mario Leporace, Hospital and University, Italy

Prof. Dr. Mario Leporace is a distinguished Clinical Radiologist at the Department of Nuclear Medicine and Theragnostics, “Mariano Santo” Hospital, Cosenza, Italy. With expertise in oncologic imaging, hybrid and molecular imaging, and cardiovascular radiology, he is renowned for his advanced diagnostic work using X-ray, CT, MRI, PET/CT, and SPECT/CT. He holds a Master’s in Interventional Oncology and has contributed to over 15 peer-reviewed publications. His professional journey spans top institutions in Rome and Cosenza, marking a career dedicated to innovation in radiology and nuclear medicine.

Publication Profile

Scopus

Education

Prof. Dr. Mario Leporace 🎓 is a distinguished expert in interventional oncology and radiology. In 2022, he earned a Master’s Degree in Interventional Oncology from Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome, with a thesis on thermal ablation of bone metastases 🔥🦴. From 2001 to 2005, he completed his post-graduate certification in Radiology at the University of Rome “Tor Vergata” 🏥, graduating cum laude with a thesis on hybrid imaging 🧠📸. He also obtained his Degree in Medicine and Surgery from the same university (1995–2001), graduating with top honors and a thesis in vascular imaging 🫀🧬.

Experience

Prof. Dr. Mario Leporace 🩺 has an extensive career in radiology and nuclear medicine, showcasing over two decades of dedicated medical service. Since October 2017, he has been serving in the Department of Nuclear Medicine and Theragnostics at “Mariano Santo” Hospital in Cosenza, Italy ⚛️🏥. From May 2016 to September 2017, he worked at the Department of Radiology, “Annunziata” Hospital 🏨. Earlier, from March 2006 to April 2016, he contributed to the European Hospital in Rome, and concurrently, from November 2005 to April 2016, served at the Aurelia Hospital in Rome 🏛️🔬, strengthening his clinical expertise across institutions.

Research Focus

Prof. Dr. Mario Leporace focuses his research on Thermal Ablation with Magnetic Resonance-guided Focused Ultrasound Surgery (MRgFUS) 🔬🧠. His work bridges medical physics and oncological applications, exploring non-invasive treatments that use focused ultrasound energy to thermally ablate tumors with MRI precision guidance 🎯. This technique offers cutting-edge therapeutic possibilities in fields such as oncology, neurology, and women’s health 🧬💡. Prof. Leporace’s contributions advance both the clinical outcomes and technological innovation of MRgFUS, making him a key figure in image-guided therapy, minimally invasive surgery, and cancer treatment research .

Publication Top Notes

The Thermal Ablation with MRgFUS: From Physics to Oncological Applications

Nigatu Gebrehiwot | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Nigatu Gebrehiwot | Precision Medicine | Best Researcher Award

Dr. Nigatu Gebrehiwot, Zhengzhou University, China

Dr. Nigatu Gebrehiwot is a dedicated PhD candidate in Pharmacology at Zhengzhou University, China, specializing in drug safety evaluation. He holds a Master’s in Clinical and Administrative Pharmacy from Xi’an Jiaotong University and a Bachelor of Pharmacy from Mekelle University, where he was recognized as an outstanding student. A published researcher and global presenter, Dr. Gebrehiwot has earned accolades including recognition at ISPOR in Barcelona. He is actively involved in multiple international scientific societies and brings strong expertise in pharmacotherapy, academic writing, and collaborative healthcare research. His work explores methionine metabolism and innovative therapeutic strategies.

Publication Profile

Orcid

Education

Dr. Nigatu Gebrehiwot holds a Master’s degree in Clinical and Administrative Pharmacy from Xi’an Jiaotong University, where his research earned an award at the 21st European Congress ISPOR Health Outcome Research Conference in Barcelona, Spain. 🏅 He also earned a Bachelor’s degree in Pharmacy from Mekelle University, where he was recognized as the most outstanding student in his class. 🎓 His academic achievements reflect his dedication to advancing the field of pharmacy, blending clinical expertise with research excellence. Dr. Gebrehiwot’s work continues to impact the healthcare landscape positively.

Experience

Dr. Nigatu Gebrehiwot is currently a Ph.D. candidate in Pharmacology at the Center for Drug Safety Evaluation and Research, Zhengzhou University, Henan, China, since September 2022. 🎓 Prior to this, he served as the Principal Scientific Officer at the Federal Ministry of Health (FMOH) in Ethiopia from June 2020 to 2021. During his tenure, Dr. Gebrehiwot managed national disease programs and medicines, overseeing the funding and evaluation of treatment guidelines and drug therapy protocols in accordance with Ethiopian legislation and EFDA guidelines. 💊 He also led technical committees focused on antimicrobial therapy, cancer, and chronic disease management.

Awards

Dr. Nigatu Gebrehiwot received a prestigious award for his research abstract at the 21st European Congress ISPOR Health Outcome Research conference in Barcelona, Spain. 🏆 This recognition underscores the significant impact of his work in the field of pharmacology and health outcome research. 🌍 His contributions continue to advance knowledge and influence healthcare practices, making him a respected figure in his field. 💡 Dr. Gebrehiwot’s dedication to research excellence and his ability to address critical health issues have earned him well-deserved acknowledgment on an international stage.

Research Focus

Dr. Nigatu Tadesse’s research primarily focuses on molecular alterations in disease processes, with an emphasis on metabolic pathways and their potential as diagnostic and therapeutic targets. His work on gastric intestinal metaplasia and methionine metabolism sheds light on novel approaches to diagnosis and treatment. Additionally, Dr. Tadesse has contributed significantly to pharmacology, particularly the study of traditional medicines like Dioscorea zingiberensis, investigating its phytochemistry, clinical applications, and toxicity. His research also extends to industrial processes, such as wastewater treatment in diosgenin production. His interdisciplinary work connects biomedicine, pharmacology, and environmental science.

Publication Top Notes

Molecular Alterations in Gastric Intestinal Metaplasia Shed Light on Alteration of Methionine Metabolism: Insight into New Diagnostic and Treatment Approaches

Knowledge, attitude and antibiotic prescribing patterns of medical doctors providing free healthcare in the outpatient departments of public hospitals in Sierra Leone: A national cross-sectional study

Dioscorea zingiberensis C. H. Wright: An overview on its traditional use, phytochemistry, pharmacology, clinical applications, quality control, and toxicity

First total synthesis of a novel amide alkaloid derived from Aconitum taipeicum and its anticancer activity

Methods to treat the industrial wastewater in diosgenin enterprises produced from Diosorea zingiberensis C. H. Wright

Safety investigation on total steroid saponins extracts from Dioscorea zingiberensis C.H. Wright: Sub-acute and chronic toxicity studies on dogs

Dr. ANTHOULA LAZARIS| Precision Medicine|Best Researcher Award

Published on by Top Pharmaceutical

Dr. ANTHOULA LAZARIS, Precision Medicine,Best Researcher Award

Dr. ANTHOULA LAZARIS, at MCGILL UNIV. HEALTH CTR,Canada

PROFILE

scopus

📚 Early Academic Pursuits :

Anthoula Lazaris began her academic journey with a B.Sc. in Microbiology and Immunology from McGill University (1983-1986), where she developed a solid foundation in the biological sciences. She continued at McGill, earning a Ph.D. in Biochemistry from the Faculty of Medicine (1988-1992). Her postdoctoral studies took her to Leiden, The Netherlands, where she further honed her expertise in Medical Biochemistry (1992-1994). This robust educational background laid the groundwork for her illustrious career in academia and biotechnology.

🏢Professional Endeavors :

Lazaris has accumulated over 30 years of combined experience in academia and industry, holding management and senior-level positions. Currently, she is a scientist at the Research Institute of the McGill University Health Centre (RI-MUHC), focusing on metastatic and metabolic diseases with an emphasis on translational research. Her career highlights include:

  • Liver Disease Biobank: In 2011, Lazaris established a Liver Disease Biobank in collaboration with Dr. P Metrakos, collecting biospecimens from patients with liver-related diseases.
  • Quebec Extracellular Vesicle Consortium: She spearheaded this consortium with Drs. Rak and Olivier, demonstrating her leadership in collaborative research initiatives.
  • CIHR Training Grant: Lazaris co-wrote and secured a substantial CIHR training grant for the Goodman Cancer Centre, illustrating her proficiency in obtaining competitive funding.

🔬Contributions and Research Focus :

Lazaris’s research contributions span several critical areas:

  • Metastatic Disease: She focuses on colorectal cancer liver metastases (CRCLM), investigating molecular mechanisms to predict therapeutic responses and developing new biomarkers.
  • Translational Research: Her work bridges basic and clinical research, aiming to translate findings into precision therapies for cancer patients. Notably, her research on predictors of therapeutic responses to antiangiogenic agents has been groundbreaking.
  • Liver Diseases: Lazaris’s research also covers hepatocellular carcinoma, cholangiocarcinomas, and NAFLD/NASH, contributing to the broader understanding of these conditions.

🏆Accolades and Recognition :

Throughout her career, Lazaris has received numerous accolades:

  • Scientific American Award: In 2002, she was recognized in the category of Research Leader in Chemical and Materials for her work on transgenic animals producing spider silk.
  • Genome Canada White Paper: She spearheaded the writing of a white paper on “Disease Mechanisms,” which was integrated into Genome Quebec’s strategic plan.
  • Scientific Publications: Her research has been published in prestigious journals like Nature and Science, highlighting her contributions to molecular biology and oncology.

🌍Impact and Influence :

Lazaris’s work has had a profound impact on both the scientific community and public health:

  • Innovations in Biotechnology: She was part of the team that demonstrated the first expression of soluble spider silk, which can be spun into fibers with remarkable mechanical properties.
  • Transgenic Research Network: As the Executive Director of the Quebec Transgenic Research Network, Lazaris unified the capabilities of researchers across Quebec, securing significant funding and fostering collaborative research.
  • Cloned Animals: She was part of the team that generated the world’s first cloned goat and Canada’s first large transgenic animal, showcasing her pioneering contributions to genetic engineering.

🌟Legacy and Future Contributions :

Anthoula Lazaris’s legacy is marked by her pioneering research, leadership in collaborative scientific endeavors, and significant contributions to translational medicine. Her work continues to influence the fields of molecular biology, biotechnology, and cancer research. Looking forward, Lazaris is expected to further her contributions to personalized medicine, leveraging her extensive experience and innovative approach to address pressing challenges in healthcare. Her dedication to translational research and collaborative spirit ensures that her impact will be felt for years to come.

🎓Publication 

Predictive biomarker discovery in cancer using a unique AI model based on set theory

Hepatic stellate cell stearoyl co-A desaturase activates leukotriene B4 receptor 2 – β-catenin cascade to promote liver tumorigenesis

    • Authors :Sinha, S., Aizawa, S., Nakano, Y., … Guccione, E., Tsukamoto, H.
    • Journal   :Nature Communications
    • Year       : 2023

Targeting Liver Metastases to Potentiate Immunotherapy in MS-Stable Colorectal Cancer—A Review of the Literature

  • Authors  :, Zlotnik, O., Krzywon, L., Bloom, J., … Lazaris, A., Metrakos, P.
  • Journal    :Cancers
  • Year         :  2023

Isolation of extracellular vesicles from human plasma samples: The importance of controls

  • Authors  :Tsamchoe, M., Petrillo, S., Lazaris, A., Metrakos, P.
  • Journal   : Biotechnology Journal
  • Year        :   2023

A Retrospective Study on the Role of Metformin in Colorectal Cancer Liver Metastases

  • Authors  :Rada, M., Krzywon, L., Petrillo, S., Lazaris, A., Metrakos, P.
  • Journal   : Biotechnology 
  • Year        :  2023